Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) — Cash Flow-to-Debt Ratio
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has a Cash Flow-to-Debt Ratio of -0.83x as of September 2025, meaning its operating cash flow of $-4.51 Million could theoretically repay -1% of its total liabilities ($5.43 Million) in one year. See Eupraxia Pharmaceuticals Inc. Common Sto (EPRX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eupraxia Pharmaceuticals Inc. Common Stock Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Eupraxia Pharmaceuticals Inc. Common Stock across 8 annual periods. Also explore how fast is Eupraxia Pharmaceuticals Inc. Common Sto growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
Year-by-year debt coverage analysis for Eupraxia Pharmaceuticals Inc. Common Stock. For market capitalisation and broader financial context, see EPRX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -9.67x | $-29.99 Million | $3.10 Million | ▼ -802.5% |
| 2023 | -1.07x | $-20.75 Million | $19.37 Million | ▼ -20.0% |
| 2022 | -0.89x | $-14.40 Million | $16.13 Million | ▲ +6.7% |
| 2021 | -0.96x | $-11.58 Million | $12.10 Million | ▼ -5375.2% |
| 2020 | -0.02x | $-403.78K | $23.12 Million | ▲ +92.8% |
| 2019 | -0.24x | $-5.17 Million | $21.42 Million | ▲ +58.4% |
| 2018 | -0.58x | $-8.32 Million | $14.34 Million | ▲ +91.9% |
| 2017 | -7.20x | $-5.30 Million | $735.82K | — |